VSTM

Biotechnology Uncategorized VSTM

Verastem posts preliminary 2025 revenue, plans clinical updates in 2026

Feb 4, 2026

Biotechnology IMRX RVMD Uncategorized VSTM

Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer

Jan 7, 2026

Biotechnology Uncategorized VSTM

Verastem ends trial of Avmapki Fakzynja combo with Amgen’s Lumakras in NSCLC

Dec 29, 2025

Biotechnology Uncategorized VSTM

Verastem Oncology announces management changes

Dec 15, 2025

Biotechnology SA Transcripts Uncategorized VSTM

Verastem (VSTM) Investor Presentation – Slideshow

Aug 14, 2022